Pilot study of vascular health in survivors of osteosarcoma

Pediatric Blood and Cancer

Volumn 60, Issue 10, 2013, Pages 1703-1708

  Mulrooney, Daniel A ^a,b   Ness, Kirsten K ^a   Huang, Sujuan ^a   Solovey, Anna ^c   Hebbel, Robert P ^c   Neaton, James D ^c   Clohisy, Denis R ^c   Kelly, Aaron S ^c   Neglia, Joseph P ^c  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Osteosarcoma; Survivorship; Vascular late effects

Indexed keywords

APOLIPOPROTEIN B; C REACTIVE PROTEIN; CARBOPLATIN; CISPLATIN; DOXORUBICIN; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1;

ADOLESCENT; ADULT; ARTICLE; BLOOD VESSEL INJURY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVOR; CARDIOVASCULAR RISK; CHILD; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MALE; OSTEOSARCOMA; PILOT STUDY; POPULATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SCHOOL CHILD; TRIACYLGLYCEROL BLOOD LEVEL;

OSTEOSARCOMA; SURVIVORSHIP; VASCULAR LATE EFFECTS;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; ATHEROSCLEROSIS; C-REACTIVE PROTEIN; CHILD; COHORT STUDIES; DYSLIPIDEMIAS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; LIPIDS; MALE; OSTEOSARCOMA; PILOT PROJECTS; SURVIVORS; VASCULAR CELL ADHESION MOLECULE-1; VASCULITIS;

EID: 84881539670     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24610     Document Type: Article

References (36)

1. Mariotto AB, Rowland JH, Yabroff KR, et al. Long-term survivors of childhood cancers in the United States. Cancer Epidemiol Biomarkers Prev 2009; 18:1033-1040.
2. Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006; 355:1572-1582.
3. Mertens AC, Liu Q, Neglia JP, et al. Cause-specific late mortality among 5-year survivors of childhood cancer: The Childhood Cancer Survivor Study. J Natl Cancer Inst 2008; 100:1368-1379.
4. Hancock SL, Donaldson SS, Hoppe RT. Cardiac disease following treatment of Hodgkin's disease in children and adolescents. J Clin Oncol 1993; 11:1208-1215.
5. Bowers DC, Liu Y, Leisenring W, et al. Late-occurring stroke among long-term survivors of childhood leukemia and brain tumors: A report from the Childhood Cancer Survivor Study. J Clin Oncol 2006; 24:5277-5282.
6. Bowers DC, McNeil DE, Liu Y, et al. Stroke as a late treatment effect of Hodgkin's disease: A report from the Childhood Cancer Survivor Study. J Clin Oncol 2005; 23:6508-6515.
7. Krull KR, Sabin ND, Reddick WE, et al. Neurocognitive function and CNS integrity in adult survivors of childhood hodgkin lymphoma. J Clin Oncol 2012; 30:3618-3624.
8. Mulrooney DA, Blaes AH, Duprez D. Vascular injury in cancer survivors. J Cardiovasc Transl Res 2012; 5:287-295.
9. Tribble DL, Barcellos-Hoff MH, Chu BM, et al. Ionizing radiation accelerates aortic lesion formation in fat-fed mice via SOD-inhibitable processes. Arterioscler Thromb Vasc Biol 1999; 19:1387-1392.
10. Brosius FC III, Waller BF, Roberts WC. Radiation heart disease. Analysis of 16 young (aged 15 to 33 years) necropsy patients who received over 3, 500 rads to the heart. Am J Med 1981; 70:519-530.
11. Dengel DR, Ness KK, Glasser SP, et al. Endothelial function in young adult survivors of childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2008; 30:20-25.
12. Chow AY, Chin C, Dahl G, et al. Anthracyclines cause endothelial injury in pediatric cancer patients: A pilot study. J Clin Oncol 2006; 24:925-928.
13. Mulrooney DA, Ness KK, Solovey A, et al. Pilot study of vascular health in survivors of Hodgkin lymphoma. Pediatr Blood Cancer 2012; 59:285-289.
14. Solovey A, Lin Y, Browne P, et al. Circulating activated endothelial cells in sickle cell anemia. N Engl J Med 1997; 337:1584-1590.
15. Friedman GD, Cutter GR, Donahue RP, et al. CARDIA: Study design, recruitment, and some characteristics of the examined subjects. J Clin Epidemiol 1988; 41:1105-1116.
16. Camici PG, Crea F. Coronary microvascular dysfunction. N Engl J Med 2007; 356:830-840.
17. Wu S, Ko YS, Teng MS, et al. Adriamycin-induced cardiomyocyte and endothelial cell apoptosis: In vitro and in vivo studies. J Mol Cell Cardiol 2002; 34:1595-1607.
18. Murata T, Yamawaki H, Yoshimoto R, et al. Chronic effect of doxorubicin on vascular endothelium assessed by organ culture study. Life Sci 2001; 69:2685-2695.
19. Jenei Z, Bardi E, Magyar MT, et al. Anthracycline causes impaired vascular endothelial function and aortic stiffness in long term survivors of childhood cancer. Pathol Oncol Res 2012; DOI 10.1007/s12253-102-9589-6
20. Mulrooney DA, Yeazel MW, Kawashima T, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: Retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 2009; 339:b4606.
21. Meinardi MT, Gietema JA, van der Graaf WT, et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 2000; 18:1725-1732.
22. Huddart RA, Norman A, Shahidi M, et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 2003; 21:1513-1523.
23. Nuver J, Smit AJ, Sleijfer DT, et al. Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. Eur J Cancer 2004; 40:701-706.
24. de Vos FY, Nuver J, Willemse PH, et al. Long-term survivors of ovarian malignancies after cisplatin-based chemotherapy; cardiovascular risk factors and signs of vascular damage. Eur J Cancer 2004; 40:696-700.
25. Charakida M, Deanfield JE, Halcox JP. Childhood origins of arterial disease. Curr Opin Pediatr 2007; 19:538-545.
26. Ridker PM. High-sensitivity C-reactive protein: Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001; 103:1813-1818.
27. Greenland P, Alpert JS, Beller GA, et al. 2010; ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: Executive summary: A report of the American college of cardiology foundation/American heart association task force on practice guidelines. Circulation 122:2748-2764.
28. Bermudez V, Arraiz N, Aparicio D, et al. Lipoprotein(a): From molecules to therapeutics. Am J Ther 2010; 17:263-273.
29. Erqou S, Kaptoge S, Perry PL, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009; 302:412-423.
30. Bostom AG, Cupples LA, Jenner JL, et al. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study. JAMA 1996; 276:544-548.
31. Borissoff JI, Spronk HM, Ten Cate H. The hemostatic system as a modulator of atherosclerosis. N Engl J Med 2011; 364:1746-1760.
32. Folsom AR, Wu KK, Rosamond WD, et al. Prospective study of hemostatic factors and incidence of coronary heart disease: The Atherosclerosis risk in communities (ARIC) study. Circulation 1997; 96:1102-1108.
33. Blann AD, Woywodt A, Bertolini F, et al. Circulating endothelial cells. Biomarker of vascular disease. Thromb Haemost 2005; 93:228-235.
34. Vaughn DJ, Palmer SC, Carver JR, et al. Cardiovascular risk in long-term survivors of testicular cancer. Cancer 2008; 112:1949-1953.
35. Cybulsky MI, Iiyama K, Li H, et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest 2001; 107:1255-1262.
36. Libby P. Inflammation in atherosclerosis. Nature 2002; 420:868-874.